Closing the gap in women´s health:
3rd Nuvisan Drug Discovery Innovation Challenge

Overview

Drug discovery in women’s health has gained renewed importance, as scientific and clinical communities strive to close long-standing gaps in our understanding of gender-specific biology and treatments. Historically, low representation in both organised patient groups and research has meant that, until relatively recently, many conditions that uniquely or disproportionately affect women have been deprioritised in efforts to characterise and treat them. Advances in precision medicine, genomics, and AI now offer powerful tools to develop therapies for reproductive health, oncology, cardiovascular disease, and menopause-related conditions. These developments could represent a paradigm shift for women´s health. Those of us active in therapeutic discovery now have a unique opportunity to reshape therapeutic development, create equity, and elevate health outcomes for women worldwide.

Nuvisan: fostering innovation in women´s health

To support scientific innovation in this field, Nuvisan — a CRO driven by science — brings together innovators and investors to create solutions and foster new partnerships for drug discovery projects.

The 3rd Nuvisan Drug Discovery Innovation challenge is seeking novel ideas that address woman´s health and associated conditions.

Examples of focus areas include:

• Reproductive and mammary health
• Endometriosis, adenomyosis, uterine fibroids, polycystic ovary syndrome
• Infertility and next-generation contraceptive approaches
• Hormonal dysregulation.
• Female cancers
• Breast, ovarian, cervical and endometrial cancers
• Novel targets, modalities, biomarkers and precision-medicine strategies.
• Autoimmune & inflammatory diseases with high female prevalence
• Systemic lupus erythematosus (SLE)
• Raynaud’s and Sjögren’s syndrome
• Autoimmune thyroid diseases.